Abu Dhabi Health Services Company
11
3
3
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Assessing the Burden of Respiratory Syncytial Virus (RSV)
Role: lead
Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis
Role: lead
The Effect of Gum Arabic (GA) on Residual Renal Function in Adult Dialysis Patients in Abu Dhabi
Role: lead
Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City
Role: lead
Healthcare Professionals' Attitude Towards Clinical Research in the United Arab Emirates
Role: lead
Knowledge of Adolescent Well-care Visits and Attitudes Amongst Physicians
Role: lead
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis
Role: lead
Knowledge Attitude and Practice Regarding Bloodstream Bacterial Infections and Antibiotics Usage Among Doctors.
Role: lead
A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above
Role: collaborator
Validation of Prognostic Clinical Risk Scores in Predicting Outcome for Patients With COVID-19 at Initial Triage
Role: collaborator
Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain
Role: lead
All 11 trials loaded